Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Asthma D001249 52 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Thrombosis D013927 49 associated lipids
Fatty Liver D005234 48 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Hyperalgesia D006930 42 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Li H et al. Select dietary phytochemicals function as inhibitors of COX-1 but not COX-2. 2013 PLoS ONE pmid:24098505
Leclerc P et al. Characterization of a human and murine mPGES-1 inhibitor and comparison to mPGES-1 genetic deletion in mouse models of inflammation. 2013 Prostaglandins Other Lipid Mediat. pmid:24045148
Vasudevan C et al. The effect of parenteral lipid emulsions on pulmonary hemodynamics and eicosanoid metabolites in preterm infants: a pilot study. 2013 Nutr Clin Pract pmid:24177284
Snider AJ et al. Inhibition of sphingosine kinase-2 in a murine model of lupus nephritis. 2013 PLoS ONE pmid:23301082
Xue YT et al. Effect of anger on endothelial-derived vasoactive factors in spontaneously hypertensive rats. 2013 Heart Lung Circ pmid:23261325
Gao H et al. Effects of Yerba Mate tea (Ilex paraguariensis) on vascular endothelial function and liver lipoprotein receptor gene expression in hyperlipidemic rats. 2013 Fitoterapia pmid:23266732
Carroll RC et al. A comparison of VerifyNowR with PlateletMappingR--detected aspirin resistance and correlation with urinary thromboxane. 2013 Anesth. Analg. pmid:23302970
Towhid ST et al. Stimulation of platelet death by vancomycin. 2013 Cell. Physiol. Biochem. pmid:23363637
Ren R et al. Modulation of platelet aggregation-related eicosanoid production by dietary F-fucoidan from brown alga Laminaria japonica in human subjects. 2013 Br. J. Nutr. pmid:23374164
Gautier-Veyret E et al. Intermittent hypoxia-activated cyclooxygenase pathway: role in atherosclerosis. 2013 Eur. Respir. J. pmid:23060635
Xue J et al. Inhibitory effects of Qushuanling Capsule () on thrombus formation and platelet aggregation in rats. 2013 Chin J Integr Med pmid:23001461
Maenthaisong R et al. Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. 2013 Apr-Jun Int J Immunopathol Pharmacol pmid:23755755
Dudley A et al. Cyclooxygenase expression and platelet function in healthy dogs receiving low-dose aspirin. 2013 Jan-Feb J. Vet. Intern. Med. pmid:23278865
John F et al. Elevated levels of leukotriene B4 and thromboxane B2 distinguish chest pain of cardiac and non cardiac origin. 2013 May-Jun Indian Heart J pmid:23809385
Yu C et al. Effects of danshensu on platelet aggregation and thrombosis: in vivo arteriovenous shunt and venous thrombosis models in rats. 2014 PLoS ONE pmid:25375124
Salazar F et al. Renal effects induced by prolonged mPGES1 inhibition. 2014 Am. J. Physiol. Renal Physiol. pmid:24197070
Kawai VK et al. Suboptimal inhibition of platelet cyclooxygenase 1 by aspirin in systemic lupus erythematosus: association with metabolic syndrome. 2014 Arthritis Care Res (Hoboken) pmid:24022862
Elsheikh W et al. Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer. 2014 Nitric Oxide pmid:24747869
Suarez-Kurtz G Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of oxicam NSAIDs. 2014 Pharmacogenet. Genomics pmid:25003537
Lee HI et al. Response to Suarez-Kurtz's comments on strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals. 2014 Pharmacogenet. Genomics pmid:25003538
Shan MQ et al. [Comparative study on effects of Rubiae Radix et Rhizoma and carbonized Rubiae Radix et Rhizoma on acute blood stasis rat model]. 2014 Zhongguo Zhong Yao Za Zhi pmid:24946554
Zhou K et al. A CAPE analogue as novel antiplatelet agent efficiently inhibits collagen-induced platelet aggregation. 2014 Pharmazie pmid:25158573
Maurer K et al. Acetylsalicylic acid enhances tachyphylaxis of repetitive capsaicin responses in TRPV1-GFP expressing HEK293 cells. 2014 Neurosci. Lett. pmid:24495935
Togna AR et al. 4-Methylcoumarin derivatives with anti-inflammatory effects in activated microglial cells. 2014 Biol. Pharm. Bull. pmid:24389482
Osmond DA et al. Clopidogrel preserves whole kidney autoregulatory behavior in ANG II-induced hypertension. 2014 Am. J. Physiol. Renal Physiol. pmid:24477682
Cathcart MC et al. Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer. 2014 Biochim. Biophys. Acta pmid:24480048
Umar A et al. Effect of Ocimum basilicum L. on cyclo-oxygenase isoforms and prostaglandins involved in thrombosis. 2014 J Ethnopharmacol pmid:24412551
Sahota T et al. Model-based analysis of thromboxane Bâ‚‚ and prostaglandin Eâ‚‚ as biomarkers in the safety evaluation of naproxen. 2014 Toxicol. Appl. Pharmacol. pmid:24667227
Gonçalves LH et al. Acetylsalicylic acid therapy: influence of metformin use and other variables on urinary 11-dehydrothromboxane B2 levels. 2014 Clin. Chim. Acta pmid:24316050
Jiménez-Romero C et al. Dactyloditerpenol acetate, a new prenylbisabolane-type diterpene from Aplysia dactylomela with significant in vitro anti-neuroinflammatory activity. 2014 Bioorg. Med. Chem. Lett. pmid:24279991
Lee HI et al. Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals. 2014 Pharmacogenet. Genomics pmid:24322170
Voisin V et al. Protection of Wistar-Furth rats against postischaemic acute renal injury: role for nitric oxide and thromboxane? 2014 Clin. Exp. Pharmacol. Physiol. pmid:25115485
Chou YI et al. Correlations of platelet-derived microparticles with thromboxane B2, platelet-activating factor, endothelin-1, and neutrophil to lymphocyte ratio in patients with coronary intermediate lesions. 2014 Biomarkers pmid:25391885
Zhu Y et al. Effects and mechanisms of Fenofibrate on the secretion of vascular endothelial contraction factors in hypertensive rats. 2014 Genet. Mol. Res. pmid:25078582
Tachi M et al. Mass spectrometric determination of prostanoids in rat hypothalamic paraventricular nucleus microdialysates. 2014 Auton Neurosci pmid:24447364
Fuentes E et al. A novel role of Eruca sativa Mill. (rocket) extract: antiplatelet (NF-κB inhibition) and antithrombotic activities. 2014 Nutrients pmid:25514563
Santos-Gallego CG and Badimon JJ The sum of two evils: pneumonia and myocardial infarction: is platelet activation the missing link? 2014 J. Am. Coll. Cardiol. pmid:25444148
Cangemi R et al. Platelet activation is associated with myocardial infarction in patients with pneumonia. 2014 J. Am. Coll. Cardiol. pmid:25444147
Shinohara M et al. Cell-cell interactions and bronchoconstrictor eicosanoid reduction with inhaled carbon monoxide and resolvin D1. 2014 Am. J. Physiol. Lung Cell Mol. Physiol. pmid:25217660
Hong S et al. Maresin-like lipid mediators are produced by leukocytes and platelets and rescue reparative function of diabetes-impaired macrophages. 2014 Chem. Biol. pmid:25200603
Tong B et al. [Atorvastatin inhibits platelet aggregation and activation following carotid balloon injury in cholesterol-fed rabbits]. 2014 Nan Fang Yi Ke Da Xue Xue Bao pmid:25176087
Kaplon-Cieslicka A et al. Younger age, higher body mass index and lower adiponectin concentration predict higher serum thromboxane B2 level in aspirin-treated patients with type 2 diabetes: an observational study. 2014 Cardiovasc Diabetol pmid:25123549
Hayashi G et al. Frataxin deficiency increases cyclooxygenase 2 and prostaglandins in cell and animal models of Friedreich's ataxia. 2014 Hum. Mol. Genet. pmid:25104852
Floyd CN et al. Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects. 2014 Br J Clin Pharmacol pmid:25099258
Zhu SH et al. Protective effect of indomethacin in renal ischemia-reperfusion injury in mice. 2014 J Zhejiang Univ Sci B pmid:25091992
Basili S et al. Aspirin reload before elective percutaneous coronary intervention: impact on serum thromboxane b2 and myocardial reperfusion indexes. 2014 Circ Cardiovasc Interv pmid:25074252
Lattanzio S et al. Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin. 2014 J Am Heart Assoc pmid:25037197
Santilli F et al. Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. 2014 J Am Heart Assoc pmid:25037196
Patrignani P et al. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. 2014 J. Thromb. Haemost. pmid:24942808
Reddoch KM et al. Hemostatic function of apheresis platelets stored at 4°C and 22°C. 2014 Shock pmid:24169210